| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |